| **Study Reference** | **Participant Characteristics** | **Intervention; Duration** | **Incident Vertebral Fracture****Risk in Treatment Group; Risk in Control Group****(RR [95% CI])** | **Incident Nonvertebral Fracture****Risk in Treatment Group; Risk in Control Group****(RR [95% CI])** | **Incident Hip Fracture****Risk in Treatment Group; Risk in Control Group****(RR [95% CI])** | **Other Incident Fractures****Risk in Treatment Group; Risk in Control Group****(RR [95% CI])** | **Quality Rating** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Greenspan et. al, 2007 36 | Postmenopausal women with mean age of 64.4 years; T-score ≤ -3.0; no prevalent vertebral fractures or T-score -2.5 with 1 to 4 vertebral fractures; mean T-score -2.2; 19% with prior vertebral fracture | Parathyroid hormone 100 µg daily injection; 18 months | No baseline fracture: 7/1050/ 21/1011 RR: 0.32 (0.14-0.75)With baseline fracture: 10/236, 21/235; RR 0.47 (0.22-0.98) | 72/1286; 72/1246RR: 0.97 (0.71-1.33) | NR | NR | Fair |
| Orwoll et. al, 2003240 | Men with mean age 59 years; mean T-score -2.7; unknown prior fracture | Teriparatide 20 or 40 µg daily injection; mean duration of 11 months | NR | 2/151 (20 ug); 1/139 (40 ug);3/147 (placebo)RR: 0.65 (0.11-3.83)RR: 0.35 (0.04-3.35) | NR | NR | Fair |

**Abbreviations:** CI=confidence interval; NR=not reported; RR=risk ratio; ug=microgram.